Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women

被引：78

作者：

Kemp, Troy J. ^{[1
]}

Garcia-Pineres, Alfonso ^{[1
]}

Falk, Roni T. ^{[2
]}

Poncelet, Sylviane ^{[3
]}

Dessy, Francis ^{[3
]}

Giannini, Sandra L. ^{[3
]}

Rodriguez, Ana Cecilia ^{[4
]}

Porras, Carolina ^{[4
]}

Herrero, Rolando ^{[4
]}

Hildesheim, Allan ^{[2
]}

Pinto, Ligia A. ^{[1
]}

机构：

[1] NCI Frederick, SAIC Frederick Inc, HPV Immunol Lab, Frederick, MD 21702 USA

[2] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA

[3] GlaxoSmithKline Biol, Res & Dev, B-1330 Rixensart, Belgium

[4] Proyecto Epidemiol Guanacaste, San Jose, Costa Rica

来源：

VACCINE | 2008年 / 26卷 / 29-30期

关键词：

human papillomavirus; neutralization assay; cervical secretions;

D O I：

10.1016/j.vaccine.2008.04.074

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Ideal methods to monitor HPV neutralizing antibodies induced by vaccination have not been established yet. Here, we evaluated systemic and cervical antibody levels induced by HPV16/18 AS04-adjuvanted vaccine (GlaxoSmithKline Biologicals) using a secreted alkaline phosphatase neutralization assay (SEAP-NA) and enzyme-linked immunosorbent assay (ELISA). Serum and cervical secretions from 50 vaccinated women were used to assess (1) overall assay reproducibility; (2) inter-assay and inter-specimen correlation; (3) correlations between month I and month 12 titers. Strong correlations between SEAP-NA and ELISA were observed (serum anti-HPV16/18, rho = 0.91/0.85; cervix anti-HPV16/18, rho = 0.84/0.89). Systemic and cervical antibody measures also correlated well (rho range: 0.64-0.75); except at mid-cycle (rho range: 0.28-0.65). Correlations between antibody levels at 1 and 12 months following the start of vaccination were poor (rho range: 0.16-0.38). In conclusion, HPV16/18 VLP-based ELISA is a reliable and valid method to monitor anti-HPV16/18 neutralizing potential for the first year following vaccination; however, additional studies will be required to better define the effects of the time on cycle and patterns of antibody response over time following vaccination. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：3608 / 3616

页数：9

共 31 条

[1]

[Anonymous], 1989, SELECTED PAPERS C R

[2] PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].

BOSCH, FX ;

MANOS, MM ;

MUNOZ, N ;

SHERMAN, M ;

JANSEN, AM ;

PETO, J ;

SCHIFFMAN, MH ;

MORENO, V ;

KURMAN, R ;

SHAH, KV ;

ALIHONOU, E ;

BAYO, S ;

MOKHTAR, HC ;

CHICAREON, S ;

DAUDT, A ;

DELOSRIOS, E ;

GHADIRIAN, P ;

KITINYA, JN ;

KOULIBALY, M ;

NGELANGEL, C ;

TINTORE, LMP ;

RIOSDALENZ, JL ;

SARJADI ;

SCHNEIDER, A ;

TAFUR, L ;

TEYSSIE, AR ;

ROLON, PA ;

TORROELLA, M ;

TAPIA, AV ;

WABINGA, HR ;

ZATONSKI, W ;

SYLLA, B ;

VIZCAINO, P ;

MAGNIN, D ;

KALDOR, J ;

GREER, C ;

WHEELER, C .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802

[3] IMMUNIZATION WITH VIRUS-LIKE PARTICLES FROM COTTONTAIL RABBIT PAPILLOMAVIRUS (CRPV) CAN PROTECT AGAINST EXPERIMENTAL CRPV INFECTION [J].

BREITBURD, F ;

KIRNBAUER, R ;

HUBBERT, NL ;

NONNENMACHER, B ;

TRINDINHDESMARQUET, C ;

ORTH, G ;

SCHILLER, JT ;

LOWY, DR .

JOURNAL OF VIROLOGY, 1995, 69 (06) :3959-3963

[4] Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors:: Implications for screening and prevention [J].

Castellsagué, X ;

Díaz, M ;

de Sanjosé, S ;

Muñoz, N ;

Herrero, R ;

Franceschi, S ;

Peeling, RW ;

Ashley, R ;

Smith, JS ;

Snijders, PJF ;

Meijer, CJLM ;

Bosch, FX .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (05) :303-315

[5] Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions [J].

Castle, PE ;

Rodriguez, AC ;

Bowman, FP ;

Herrero, R ;

Schiffman, M ;

Bratti, MC ;

Morera, LA ;

Schust, D ;

Crowley-Nowick, P ;

Hildesheim, A .

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (02) :399-405

[6] Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: Implication for optimal age of human papillomavirus vaccination [J].

Chen, Chih-Jung ;

Viscidi, Raphael P. ;

Chuang, Chih-Hsien ;

Huang, Yhu-Chering ;

Chiu, Cheng-Hsun ;

Lin, Tzou-Yien .

JOURNAL OF CLINICAL VIROLOGY, 2007, 38 (02) :126-130

[7] Carcinogenicity of human papillomaviruses [J].

Cogliano, V ;

Baan, R ;

Straif, K ;

Grosse, Y ;

Secretan, B ;

El Ghissassi, F .

LANCET ONCOLOGY, 2005, 6 (04) :204-204

[8] Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18 [J].

Dias, D ;

Van Doren, J ;

Schlottmann, S ;

Kelly, S ;

Puchalski, D ;

Ruiz, W ;

Boerckel, P ;

Kessler, J ;

Antonello, JM ;

Green, T ;

Brown, M ;

Smith, J ;

Chirmule, N ;

Barr, E ;

Jansen, KU ;

Esser, MT .

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (08) :959-969

[9]

Gail MH, 1996, CANCER EPIDEM BIOMAR, V5, P835

[10] Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases [J].

Garland, Suzanne M. ;

Hernandez-Avila, Mauricio ;

Wheeler, Cosette M. ;

Perez, Gonzalo ;

Harper, Diane M. ;

Leodolter, Sepp ;

Tang, Grace W. K. ;

Ferris, Daron G. ;

Steben, Marc ;

Bryan, Janine ;

Taddeo, Frank J. ;

Railkar, Radha ;

Esser, Mark T. ;

Sings, Heather L. ;

Nelson, Micki ;

Boslego, John ;

Sattler, Carlos ;

Barr, Eliav ;

Koutsky, Laura A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (19) :1928-1943

← 1 2 3 4 →